Latest Supernus News & Updates

See the latest news and media coverage for Supernus. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Supernus

Central nervous system biopharmaceutical company

indivior.com
Headquarters
Richmond, United States
Company type
Public company
Number of employees
1,000–5,000
Industry
Pharmaceuticals

Last updated

Latest news about Supernus

In short: Supernus completed its merger with Indivior, creating a CNS-focused company with $125 million in expected annual synergies.

Company announcements

Supernus

Supernus completes its merger with Indivior

The combined company is a diversified, scaled biopharmaceutical firm focused on central nervous system diseases, and will continue the Powering Recovery initiative.

Supernus

Indivior shareholders approve merger with Supernus

Approved by 94% of votes on October 15 for a November 2 closing, creating Supernus Inc trading as SUPN. The deal combines CNS-focused biopharmaceutical capabilities into a diversified company.

Supernus

Indivior declares special cash dividend contingent on merger

The $8.13 per share dividend pays after Nov 2 merger with Supernus closes. Indivior won't pay if the deal fails.

Unlock all announcements with a

Media coverage

RTTNews

Indivior Plc. Announces Climb In Q3 Income

Indivior plc. (INDV.L) reported a profit for its third quarter that Increases, from last year The company's bottom line totaled $137 million, or $1.12 per...

AInvest

Supernus's Oct 29 Report Is a Formality - the Ticker Now Trades on the Indivior Merger

Supernus merges with Indivior, converting shares into a 43.5% stake in a $2.2B CNS revenue company with 40% margins.

Unlock all articles with a

Never miss news about Supernus

Track Supernus and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.